Fecha de recepción: 13/07/2017 – Fecha de aceptación: 21/09/2017
García-Quintanilla L1,2*, Otero-Barreiro MC3*, González-Barcia M1,2, Virgós-Lamela A3, Rodríguez-Prada M1,2,
Lamas MJ1,2, Fernández-Ferreiro A1,2
1 Servicio de Farmacia. Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS) (España)
2 Grupo de Farmacología Clínica. Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS-ISCIII) (España)
3 Servicio de Cardiología. Xerencia de Xestión Integrada de Santiago de Compostela (SERGAS) (España)
*Ambos autores contribuyen por igual
____
Correspondencia:
Anxo Fernández Ferreiro
María Jesús Lamas
Xerencia Xestión Integrada de Santiago de Compostela (SERGAS)
(Servicio de Farmacia)
C/ A Choupana, s/n
15706 Santiago de Compostela
Correo electrónico: anxordes@gmail.com
Correo electrónico: maria.jesus.lamas.diaz@sergas.es
____
SUMMARY
Objective: Phlebitis is one of the major complications associated with the use of catheters, for which there are no standardized treatment protocols. The aim of this study is to analyse the use and assess the effectiveness of the Burow Solution in patients with phlebitis.
Methods: This is a prospective nine-month observational study describing the use and evaluating the efficacy and safety of a phlebitis protocol treatment with Burow Solution.
Results: During the inclusion period, the Burow Solution has been used in 35 patients with phlebitis, of whom 12 have been excluded for lack of daily follow-up. The degree of phlebitis has been grade IV in 21% (n=5) of patients, grade III in 52% (n=12), grade II in 22% (n=5) and grade I in 4% (n=1). 95% of phlebitis have been chemical, mainly caused by antibiotics. Eighty-three percent (n=19) of the patients responded to therapy by reducing the degree of phlebitis two points after three days of treatment and only 17% (n=4) did not respond, requiring topical dressings with Feparil® cream. No patient experienced adverse effects during treatment.
Conclusions: Burow Solution is a pharmaceutical compounding that has been used specially in grade III phlebitis that mainly affects the cephalic vein and that have as the first trigger the use of antibiotics. 69% of the patients have required their use for three days, observing that in 17% of cases the application of the dressings has not been effective, however, complementary studies must be done to obtain conclusive results on their effectiveness.
Key Words: Burow Solution, catheter, efficacy, pharmaceutical compounding, phlebitis, safety use.
____
Download PDF: Estudio de la Utilización, Eficacia y Seguridad de la Solución de Burow en el tratamiento de la flebitis